[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 39, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 832920, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 56, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 730050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 70, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 50, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tina  Albertson M.D., Ph.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.48, "open": 1.52, "dayLow": 1.495, "dayHigh": 1.58, "regularMarketPreviousClose": 1.48, "regularMarketOpen": 1.52, "regularMarketDayLow": 1.495, "regularMarketDayHigh": 1.58, "payoutRatio": 0.0, "beta": 2.614, "forwardPE": -0.7889447, "volume": 1012990, "regularMarketVolume": 1012990, "averageVolume": 1125668, "averageVolume10days": 1132020, "averageDailyVolume10Day": 1132020, "bid": 1.12, "ask": 1.94, "bidSize": 2, "askSize": 2, "marketCap": 146744832, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.535, "allTimeHigh": 32.645, "allTimeLow": 0.66, "priceToSalesTrailing12Months": 15.787502, "fiftyDayAverage": 1.6708, "twoHundredDayAverage": 1.711585, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 24949820, "profitMargins": 0.0, "floatShares": 84495106, "sharesOutstanding": 93468038, "sharesShort": 6793288, "sharesShortPriorMonth": 6240758, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0727, "heldPercentInsiders": 0.09715, "heldPercentInstitutions": 0.40011, "shortRatio": 6.69, "shortPercentOfFloat": 0.0761, "impliedSharesOutstanding": 93468038, "bookValue": 1.518, "priceToBook": 1.0342556, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -157127008, "trailingEps": -1.7, "forwardEps": -1.99, "enterpriseToRevenue": 2.684, "enterpriseToEbitda": -0.184, "52WeekChange": 0.121212125, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 1.57, "targetHighPrice": 32.0, "targetLowPrice": 4.0, "targetMeanPrice": 10.875, "targetMedianPrice": 8.5, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 147259008, "totalCashPerShare": 1.576, "ebitda": -135692992, "totalDebt": 25464000, "quickRatio": 5.353, "currentRatio": 5.542, "totalRevenue": 9295000, "debtToEquity": 17.952, "revenuePerShare": 0.1, "returnOnAssets": -0.32411, "returnOnEquity": -0.74283, "grossProfits": -119263000, "freeCashflow": -76102000, "operatingCashflow": -125638000, "revenueGrowth": 0.086, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -13.375799, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": 6.08108, "regularMarketPrice": 1.57, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "postMarketChangePercent": 0.636942, "postMarketPrice": 1.58, "postMarketChange": 0.00999999, "regularMarketChange": 0.09, "regularMarketDayRange": "1.495 - 1.58", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1770425526, "regularMarketTime": 1770411601, "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1125668, "fiftyTwoWeekLowChange": 0.91, "fiftyTwoWeekLowChangePercent": 1.3787879, "fiftyTwoWeekRange": "0.66 - 3.535", "fiftyTwoWeekHighChange": -1.965, "fiftyTwoWeekHighChangePercent": -0.5558699, "fiftyTwoWeekChangePercent": 12.121212, "earningsTimestamp": 1762981200, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.7, "epsForward": -1.99, "fiftyDayAverageChange": -0.10079992, "fiftyDayAverageChangePercent": -0.06033033, "twoHundredDayAverageChange": -0.14158499, "twoHundredDayAverageChangePercent": -0.08272156, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "averageAnalystRating": "1.4 - Strong Buy", "displayName": "Caribou Biosciences", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]